Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Renovis cuts staff, targets development

January 29, 2007 | A version of this story appeared in Volume 85, Issue 5

Renovis, a South San Francisco-based biotech company focused on drugs for neurological and inflammatory diseases, will eliminate approximately 50 positions, or 40% of its workforce, as part of a restructuring intended to reduce spending and focus research on late-stage preclinical drug discovery programs. The company says the move will not affect its partnership with Pfizer to develop small-molecule vanilloid receptor antagonists; clinical trials are expected to begin this year. Renovis says it is hoping to advance two programs for inflammatory disease and pain indications into clinical trials by 2008.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.